Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial

[1]  Nicola A Hanania,et al.  Lebrikizumab treatment in adults with asthma. , 2011, The New England journal of medicine.

[2]  Christopher E Brightling,et al.  Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. , 2011, American journal of respiratory and critical care medicine.

[3]  P. Gibson,et al.  Management of asthma in pregnancy guided by measurement of fraction of exhaled nitric oxide: a double-blind, randomised controlled trial , 2011, The Lancet.

[4]  C. Brightling,et al.  Refractory asthma in the UK: cross-sectional findings from a UK multicentre registry , 2010, Thorax.

[5]  I. Pavord,et al.  Mepolizumab in refractory eosinophilic asthma , 2010, Thorax.

[6]  D. Curran‐Everett,et al.  Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. , 2010, American journal of respiratory and critical care medicine.

[7]  Parameswaran Nair,et al.  Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. , 2009, The New England journal of medicine.

[8]  Ana Sousa,et al.  Mepolizumab and exacerbations of refractory eosinophilic asthma. , 2009, The New England journal of medicine.

[9]  Mike Thomas,et al.  Cluster analysis and clinical asthma phenotypes. , 2008, American journal of respiratory and critical care medicine.

[10]  J A Anderson,et al.  Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited , 2008, European Respiratory Journal.

[11]  W. Busse,et al.  A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. , 2007, American journal of respiratory and critical care medicine.

[12]  W. Busse,et al.  Severe asthma in adults: what are the important questions? , 2007, The Journal of allergy and clinical immunology.

[13]  A. Vignola,et al.  Near‐fatal asthma phenotype in the ENFUMOSA Cohort , 2007, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[14]  L. Boulet,et al.  Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations , 2006, European Respiratory Journal.

[15]  Klas Svensson,et al.  Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. , 2005, Respiratory medicine.

[16]  Stephen T Holgate,et al.  Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. , 2004, American journal of respiratory and critical care medicine.

[17]  S. Phipps,et al.  Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. , 2003, The Journal of clinical investigation.

[18]  A. Kay,et al.  Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. , 2003, American journal of respiratory and critical care medicine.

[19]  I. Pavord,et al.  Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial , 2002, The Lancet.

[20]  P Godard,et al.  Costs of asthma are correlated with severity: a 1-yr prospective study , 2002, European Respiratory Journal.

[21]  K. Chung,et al.  Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response , 2000, The Lancet.

[22]  S. Spector,et al.  Proceedings of the ATS workshop on refractory asthma: current understanding, recommendations, and unanswered questions. American Thoracic Society. , 2000, American journal of respiratory and critical care medicine.

[23]  G H Guyatt,et al.  Development and validation of a questionnaire to measure asthma control. , 1999, The European respiratory journal.

[24]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[25]  P. Barnes,et al.  The costs of asthma. , 1996, The European respiratory journal.

[26]  G. Guyatt,et al.  Measuring quality of life in asthma. , 1993, The American review of respiratory disease.

[27]  A. Adinoff,et al.  Steroid-induced fractures and bone loss in patients with asthma. , 1983, The New England journal of medicine.